This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kirby, J. T.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kirby, J. T.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, January 2004, p. 445-448, Vol. 42, No. 1
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.1.445-448.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Antimicrobial Susceptibility and Epidemiology of a Worldwide Collection of Chryseobacterium spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001)

Jeffrey T. Kirby,1 Helio S. Sader,1,2* Timothy R. Walsh,3 and Ronald N. Jones1,4

The Jones Group/JMI Laboratories, North Liberty, Iowa,1 Federal University of São Paulo, São Paulo, Brazil,2 University of Bristol, Bristol, United Kingdom,3 Tufts University School of Medicine, Boston, Massachusetts4

Received 21 July 2003/ Returned for modification 1 September 2003/ Accepted 10 October 2003


arrow
ABSTRACT
 
Limited data are available on Chryseobacterium spp. leading to an evaluation of the patient demographics and susceptibility patterns for Chryseobacterium spp. collected in the first 5 years of the SENTRY Antimicrobial Surveillance Program (1997 to 2001). Fifty isolates (24 Chryseobacterium meningosepticum, 20 Chryseobacterium indologenes, two Chryseobacterium gleum, and 4 Chryseobacterium spp. isolates) were collected. The highest Chryseobacterium prevalence was detected among the elderly. The most active antimicrobials were the newer quinolones (garenoxacin, gatifloxacin, and levofloxacin, each with a MIC at which 90 percent of the isolates are inhibited [MIC90] of 1 µg/ml and 98.0% susceptibility) followed by rifampin (MIC90, 2 µg/ml and 85.7% susceptibility). Trimethoprim-sulfamethoxazole, ciprofloxacin, and piperacillin-tazobactam also showed reasonable activity; vancomycin showed poor potency.


arrow
INTRODUCTION
 
Ubiquitous in nature, Chryseobacterium species are found primarily in soil and water. Environmental studies have revealed that these organisms can survive in chlorine-treated municipal water supplies, often colonizing sink basins and taps and creating potential reservoirs for infections inside hospital environments. Colonization of patients via contaminated medical devices involving fluids (respirators, intubation tubes, mist tents, humidifiers, incubators for newborns, ice chests, syringes, etc.) has been documented (8, 12). Contaminated surgically implanted devices such as intravascular catheters and prosthetic valves have also been reported (18). In other clinical settings, chryseobacteria have been described as etiological agents of meningitis, bacteremia, pneumonia, endocarditis, infections of skin and soft tissue, ocular infections, and other infections (6). Primarily opportunistic pathogens, they infect mainly newborns and immunocompromised hosts from all age groups.

Chryseobacterium meningosepticum is the most pathogenic member of the genus. As an agent of neonatal meningitis, it reportedly demonstrates mortality rates of up to 57% and produces severe postinfection sequelae including hydrocephalus, deafness, and developmental delay. C. meningosepticum is involved to a lesser extent in cases of pneumonia and bacterial sepsis in neonates and adults (6, 23).

Antimicrobial susceptibility data on Chryseobacterium spp. remain very limited, since this pathogen has been rarely isolated from clinical specimens. In addition, results of susceptibility testing vary when different methods are used. Results from disk diffusion methods may not be reliable, so broth reference quality microdilution tests should be performed when possible (1, 9).

Increasing concerns over the possibility of disseminating plasmid-mediated carbapenem-hydrolyzing enzymes has led researchers to characterize the natural reservoir of chromosomally linked metallo-ß-lactamases (MßLs) found in Chryseobacterium strains (3, 5). Multiple heterogeneous carbapenem-hydrolyzing enzymes have been reported in a single strain of C. meningosepticum. Investigations have also detected synergistic effects between cephalosporins and clavulanic acid, adding Ambler class A extended-spectrum ß-lactamases to the growing list of resistance mechanisms found in chryseobacteria (4, 21).

Chryseobacterium spp. are known to exhibit resistance to aminoglycosides, tetracyclines, chloramphenicol, erythromycin, clindamycin, and teicoplanin (1, 6, 14). However, some fluoroquinolones have shown favorable results (9, 25). Minocycline has also shown good in vitro activity, while susceptibility to doxycycline and trimethoprim-sulfamethoxazole appears variable. Rifampin is usually active in vitro and has been used as part of a combination therapy to clear persistent infection (11). Vancomycin alone or in combination with other agents, including rifampin, has in the past been successful in the treatment of meningitis in infants (20). However, the usefulness of vancomycin against Chryseobacterium spp. infections has more recently been questioned (6, 9). Thus, there is no optimal regimen for the treatment of Chryseobacterium spp. infections and antimicrobial therapy should be based on MIC from properly performed susceptibility tests.

The SENTRY Antimicrobial Surveillance Program is a world-wide study monitoring the susceptibility and resistance patterns of bacterial and fungal pathogens. This investigation was conducted by using results from over 119 sentinel hospitals and laboratories in North America, Latin America, Europe, and the Asia-Pacific region from the initial 5 years of the program (1997 to 2001). During this time period, over 155,811 clinical isolates were collected from several sites of infections, including bloodstream, the lower respiratory tract, skin and soft tissue, and the urinary tract. All Chryseobacterium spp. isolates collected during this period were evaluated. Fifty isolates unique to a given patient were identified and selected for detailed characterization and additional antimicrobial susceptibility testing.

Individual strains came from hospitalized patients in the Asia-Pacific region (16 strains from 7 centers), Europe (5 strains from 5 centers), Latin America (14 strains from 6 centers), and North America (15 strains from 15 centers). Each strain was tested against 47 antimicrobials, of which only selected agents were used for comparison of activity. Manufacturers for each agent supplied standard compounds that were placed in dry-form, validated microdilution panels (Trek Diagnostic Systems Inc., Cleveland, Ohio). All organisms were tested by broth microdilution methodology as specified by the NCCLS (16). Interpretation of quantitative MIC results was in accordance with NCCLS (16, 17) criteria. Selected gram-positive-active drugs were tested against Chryseobacterium spp. isolates, and the results were interpreted according to breakpoints approved for Staphylococcus or Enterococcus species by the NCCLS (17).

Multiple isolates of the same species isolated by the same medical center were selected for molecular typing. These isolates were characterized by macrorestriction analysis of chromosomal DNA by using pulsed-field gel electrophoresis (PFGE) as previously described (19, 24). Meropenem hydrolysis was evaluated for 21 randomly selected strains (11 C. indologenes and 10 C. meningosepticum isolates) by UV spectrophotometric assays (Pharmacia LKB Ultrospec II) in 1-cm light path cuvettes with readings recorded at 2-s intervals for 2 min at a wavelength of optimal absorbance (loss of substrate at 298 nm). The ability to induce MßLs was assessed by challenging mid-log growth cells with cefoxitin at 0.25 µg/ml for 2 h (26). The cells were harvested by centrifugation (12,000 x g), washed in the aforementioned buffer, and ribolysed. The ribolysed cells were centrifuged at 12,000 x g to remove cellular debris. The activities of the enzymes were converted to a specific activity (micromolar substrate hydrolyzed/minute/milligram of protein) using -2,500 as the extinction coefficient for meropenem as previously described (2).

The 50 isolates were collected from 33 medical centers in 16 countries. Only three medical centers sent multiple isolates of the same species. Chryseobacterium spp. represented only 0.27% (50 of 18,569) of the processed nonfermentative gram-negative bacilli and 0.03% (50 of 155,811) of all bacterial isolates collected by the SENTRY Program during the 5-year period evaluated (1997 to 2001). In addition, Chryseobacterium spp. represented only 0.10% of respiratory tract isolates and 0.03% of bloodstream infection isolates. The low frequency of this pathogen as a cause of infection is probably related to its reduced degree of pathogenicity. Some studies have shown that Chryseobacterium can be rapidly cleared by the immune system when introduced into the bloodstream or respiratory tract of a healthy animal or human host (6, 8, 22).

The most frequently isolated species was C. meningosepticum (24 isolates [48.0%]), followed by C. indologenes (20 isolates [40%]) and C. gleum (2 isolates [4.0%]). Four isolates (8.0%) could not be identified to the species level. All isolates were from hospitalized patients, and the vast majority was recovered from either lower respiratory tract (26 isolates [52.0%]) or blood cultures (23 isolates [46.0%]). The frequency of Chryseobacterium among respiratory tract specimens (0.10%; 26 of 25,657 specimens evaluated) was threefold higher than among positive blood cultures (0.03%; 23 of 74,236). Among isolates from bloodstream infections, 52.2% were C. meningosepticum and 30.4% were C. indologenes. Conversely, one-half of the isolates from the respiratory tract were C. indologenes and 42.3% were C. meningosepticum. One isolate (C. meningosepticum) was recovered from skin and/or soft tissue infection. The highest frequency of Chryseobacterium spp. infection occurred among the elderly (>=65 years old; 0.045%) and the lowest frequency occurred among children <=5 years of age (0.016%).

The quinolones showed the highest potency and spectrum of activity against the overall collection of Chryseobacterium spp. Garenoxacin was the most active quinolone (MIC50, 0.12 µg/ml; MIC90, 1 µg/ml), and this new desfluoro compound inhibited 98.0% of isolates at the proposed susceptible breakpoint for other nonfermentative gram-negative bacilli (<=2 µg/ml) (13). Gatifloxacin (MIC50, 0.25 µg/ml) and levofloxacin (MIC50, 0.5 µg/ml) also inhibited 98.0% of the isolates at susceptible breakpoints (17), and the rate of susceptibility to ciprofloxacin (MIC50, 0.5 µg/ml) was significantly lower (80.0% overall). Trimethoprim-sulfamethoxazole showed reasonable activity (87.8% susceptibility overall). Among the ß-lactams, the most active agents overall were piperacillin-tazobactam (MIC50, 4 µg/ml; 80.0% susceptibility), piperacillin (MIC50, 8 µg/ml; 74.0% susceptibility), and cefepime (MIC50, 8 µg/ml; 62.0% susceptibility). The carbapenems (6 to 12% susceptible) and the aminoglycosides (8 to 14% susceptible) exhibited poor activity against these pathogens. MßL activity was demonstrated for all isolates evaluated. Activity ranged from 381 to 788 (average 529) µmol/min/mg of protein.

Many studies have shown that vancomycin has marginal in vitro activity against Chryseobacterium spp. isolates. In addition, some reports have documented the successful use of vancomycin to treat C. meningosepticum infections, and this antimicrobial agent has been recommended as a therapeutic choice (7, 8, 10). We tested vancomycin and several other antimicrobial agents used to treat gram-positive infections, and all of these compounds showed poor activity against the contemporary Chryseobacterium spp. isolates tested. For the vast majority of strains (87.8%) the vancomycin MIC was intermediate (8 to 16 µg/ml). Rifampin was active against the majority of strains (85.7% susceptibility overall) and can be used in combination to treat severe invasive infections (10, 11).

C. meningosepticum showed slightly lower susceptibility rates to the ß-lactams (71.0% susceptibility to piperacillin-tazobactam) and to trimethoprim-sulfamethoxazole (79.2%) when compared to C. indologenes (90.0 and 95.0% susceptibility to piperacillin-tazobactam and trimethoprim-sulfamethoxazole, respectively). On the other hand, these two species had similar rates of susceptibility to fluoroquinolones and other antimicrobial agents (Table 1).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Spectrum of selected antimicrobial agents against the most frequently isolated species

Interestingly, isolates from the Asia-Pacific region showed higher rates of resistance to the ß-lactams (Table 2). The rate of susceptibility to piperacillin-tazobactam was only 50.0% in the Asia-Pacific region (16 isolates) compared to 100% in North America (15 isolates) and Europe (5 isolates) and 85.7% in Latin America (14 isolates). This higher rate of resistance may be related to the higher proportion of C. meningosepticum isolated in this region, since this species has shown higher rates of resistance than C. indologenes, especially for ß-lactams and trimethoprim-sulfamethoxazole (Table 1). Susceptibility rates did not vary greatly among regions for other classes of antimicrobial agents (Table 2).


View this table:
[in this window]
[in a new window]
  		TABLE 2. In vitro activities of selected antimicrobials against Chryseobacterium spp. according to SENTRY region

Thirteen strains (five C. indologenes and eight C. meningosepticum isolates) from three medical centers (Brazil, China, and Hong Kong) were characterized by PFGE. Among C. indologenes, three isolates from a Brazilian center had identical PFGE patterns. Two C. meningosepticum isolates from the same Brazilian medical center also shared a unique PFGE pattern. These isolates were collected from elderly patients (ages 66 to 90 years) with nosocomial pneumonia hospitalized in intensive care units (ICU). All other tested isolates had distinct chromosomal DNA profiles. The finding of two small epidemic clusters involving elderly patients hospitalized in the ICU with lower respiratory tract infections raises concern for the possible occurrence of outbreaks in this patient population. Chryseobacterium spp. colonization in patients admitted to a respiratory-surgical ICU was reported more than two decades ago, and it was linked to the municipal water supply (8). In addition, its unusual resistance to antimicrobial agents directed to gram-negative bacteria allows for favorable environmental competition and subsequent colonization. Once patients become colonized, organisms can be transmitted to noncolonized patients primarily by hand carriage (8, 15).

In summary, the results of the evaluation of a world-wide collection of unique Chryseobacterium strains indicate that (i) the newer quinolones (garenoxacin, gatifloxacin, and levofloxacin) may represent the most appropriate antimicrobial agents to treat infections caused by this pathogen, (ii) vancomycin and other anti-gram-positive antimicrobial agents may not represent satisfactory therapeutic options for Chryseobacterium infections, (iii) the production of metallo-ß-lactamase seems to be constitutive among Chryseobacterium spp., and (iv) epidemic clusters may occur among elderly patients hospitalized in ICUs. Extensive world-wide surveillance programs, such as the SENTRY Program, are extremely important to guide empirical antimicrobial therapy and clinical context of rarely isolated pathogens.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: JMI Laboratories/The Jones Group, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317. Phone: (319) 665-3370. Fax: (319) 665-3371. Email: helio-sader{at}jmilabs.com. Back


arrow
REFERENCES
 
    1
  1. Aber, R. C., C. Wennersten, and R. C. Moellering, Jr. 1978. Antimicrobial susceptibility of Flavobacteria. Antimicrob. Agents Chemother. 14:483-487.[Abstract/Free Full Text]
    2. 2
  2. Avison, M. B., C. S. Higgins, C. J. von Heidreich, P. M. Bennett, and T. R. Walsh. 2001. Plasmid location and molecular heterogeneity of the L1 and L2 ß-lactamase genes of Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 45:413-419.[Abstract/Free Full Text]
    3. 3
  3. Bellais, S., D. Aubert, T. Naas, and P. Nordmann. 2000. Molecular and biochemical heterogeneity of class B carbapenem-hydrolyzing beta-lactamases in Chryseobacterium meningosepticum. Antimicrob. Agents Chemother. 44:1878-1886.[Abstract/Free Full Text]
    4. 4
  4. Bellais, S., T. Naas, and P. Nordmann. 2002. Molecular and biochemical characterization of Ambler class A extended-spectrum beta-lactamase CGA-1 from Chryseobacterium gleum. Antimicrob. Agents Chemother. 46:966-970.[Abstract/Free Full Text]
    5. 5
  5. Bellais, S., L. Poirel, S. Leotard, and P. Nordmann. 2000. Genetic diversity of carbapenem-hydrolyzing metallo-beta-lactamases from Chryseobacterium (Flavobacterium) indologenes. Antimicrob. Agents Chemother. 44:3028-3034.[Abstract/Free Full Text]
    6. 6
  6. Bloch, K. C., R. Nadarajah, and R. Jacobs. 1997. Chryseobacterium meningosepticum: an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review. Medicine (Baltimore) 76:30-41.[CrossRef][Medline]
    7. 7
  7. Di Pentima, M. C., E. O. Mason, and S. L. Kaplan. 1998. In vitro antibiotic synergy against Flavobacterium meningosepticum: implications for therapeutic options. Clin. Infect. Dis. 26:1169-1176.[Medline]
    8. 8
  8. Du Moulin, G. C. 1979. Airway colonization by Flavobacterium in an intensive care unit. J. Clin. Microbiol. 10:155-160.[Abstract/Free Full Text]
    9. 9
  9. Fraser, S. L., and J. H. Jorgensen. 1997. Reappraisal of the antimicrobial susceptibilities of Chryseobacterium and Flavobacterium species and methods for reliable susceptibility testing. Antimicrob. Agents Chemother. 41:2738-2741.[Abstract]
    10. 10
  10. Gilbert, D. N., R. C. Moellering, and M. A. Sande. 2003. The Sanford guide to antimicrobial therapy, 3rd ed., p. 48. Antimicrobial Therapy, Inc., Hyde Park, Vt.
    11. 11
  11. Hirsh, B. E., B. Wong, T. E. Kiehn, T. Gee, and D. Armstrong. 1986. Flavobacterium meningosepticum bacteremia in an adult with acute leukemia. Use of rifampin to clear persistent infection. Diagn. Microbiol. Infect. Dis. 4:65-69.[CrossRef][Medline]
    12. 12
  12. Hoque, S. N., J. Graham, M. E. Kaufmann, and S. Tabaqchali. 2001. Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit. J. Hosp. Infect. 47:188-192.[CrossRef][Medline]
    13. 13
  13. Howard, W., D. J. Biedenbach, and R. N. Jones. 2002. Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS 284756 (T-3811) tested against non-fermentative Gram-negative bacilli. Clin. Microbiol. Infect. 8:340-344.[CrossRef][Medline]
    14. 14
  14. Hsueh, P. R., L. J. Teng, P. C. Yang, S. W. Ho, W. C. Hsieh, and K. T. Luh. 1997. Increasing incidence of nosocomial Chryseobacterium indologenes infections in Taiwan. Eur. J. Clin. Microbiol. Infect. Dis. 16:568-574.[CrossRef][Medline]
    15. 15
  15. Kienzle, N., M. Muller, and S. Pegg. 2001. Chryseobacterium in burn wounds. Burns 27:179-182.[CrossRef][Medline]
    16. 16
  16. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved Document M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    17. 17
  17. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial susceptibility testing. Thirteenth information supplement M100-S13. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    18. 18
  18. Nulens, E., B. Bussels, A. Bols, B. Gordts, and H. W. Van Landuyt. 2001. Recurrent bacteremia by Chryseobacterium indologenes in an oncology patient with a totally implanted intravenous device. Clin. Microbiol. Infect. 7:391-393.[CrossRef][Medline]
    19. 19
  19. Pfaller, M. A., R. J. Hollis, and H. S. Sader. 1992. Molecular biology—PFGE analysis of chromosomal restriction fragments, p. 10.5.c.1-10.5.c.11. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook. American Society for Microbiology, Washington, D.C.
    20. 20
  20. Ratner, H. 1984. Flavobacterium meningosepticum. Infect. Control 5:237-239.[Medline]
    21. 21
  21. Rossolini, G. M., N. Franceschini, L. Lauretti, B. Caravelli, M. L. Riccio, M. Galleni, J.-M. Frere, and G. Amicosante. 1999. Cloning of a Chryseobacterium (Flavobacterium) meningosepticum chromosomal gene (blaACME) encoding an extended-spectrum class A ß-lactamase related to the Bacteroides cephalosporinases and the VEB-1 and PER ß-lactamases. Antimicrob. Agents Chemother. 43:2193-2199.[Abstract/Free Full Text]
    22. 22
  22. Sader, H. S., R. N. Jones, and M. A. Pfaller. 1995. Relapse of catheter-related Flavobacterium meningosepticum bacteremia demonstrated by DNA macrorestriction analysis. Clin. Infect. Dis. 21:997-1000.[Medline]
    23. 23
  23. Tekerekoglu, M. S., R. Durmaz, M. Ayan, Z. Cizmeci, and A. Akinci. 2003. Analysis of an outbreak due to Chryseobacterium meningosepticum in a neonatal intensive care unit. New Microbiol. 26:57-63.[Medline]
    24. 24
  24. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.[Medline]
    25. 25
  25. Visalli, M. A., S. Bajaksouzian, M. R. Jacobs, and P. C. Appelbaum. 1997. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Antimicrob. Agents Chemother. 41:1475-1481.[Abstract]
    26. 26
  26. Walsh, T. R., A. P. MacGowan, and P. M. Bennett. 1997. Sequence analysis and enzyme kinetics of the L2 serine ß-lactamase from Stenotrophomonas maltophilia. Antimicrob. Agents Chemother. 41:1460-1464.[Abstract]

Journal of Clinical Microbiology, January 2004, p. 445-448, Vol. 42, No. 1
0095-1137/04/$08.00+0     DOI: 10.1128/JCM.42.1.445-448.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Tuon, F. F., Campos, L., Duboc de Almeida, G., Gryschek, R. C. (2007). Chryseobacterium meningosepticum as a cause of cellulitis and sepsis in an immunocompetent patient. J Med Microbiol 56: 1116-1117 [Abstract] [Full Text]  
  • Ozkalay, N., Anil, M., Agus, N., Helvaci, M., Sirti, S. (2006). Community-Acquired Meningitis and Sepsis Caused by Chryseobacterium meningosepticum in a Patient Diagnosed with Thalassemia Major.. J. Clin. Microbiol. 44: 3037-3039 [Abstract] [Full Text]  
  • Chen, G.-X., Zhang, R., Zhou, H. W. (2006). Heterogeneity of metallo-{beta}-lactamases in clinical isolates of Chryseobacterium meningosepticum from Hangzhou, China. J Antimicrob Chemother 57: 750-752 [Abstract] [Full Text]  
  • Lee, C.-C., Chen, P.-L., Wang, L.-R., Lee, H.-C., Chang, C.-M., Lee, N.-Y., Wu, C.-J., Shih, H.-I, Ko, W.-C. (2006). Fatal Case of Community-Acquired Bacteremia and Necrotizing Fasciitis Caused by Chryseobacterium meningosepticum: Case Report and Review of the Literature.. J. Clin. Microbiol. 44: 1181-1183 [Abstract] [Full Text]  
  • Cascio, A., Stassi, G., Costa, G. B, Crisafulli, G., Rulli, I., Ruggeri, C., Iaria, C. (2005). Chryseobacterium indologenes bacteraemia in a diabetic child. J Med Microbiol 54: 677-680 [Abstract] [Full Text]  
  • Christakis, G. B., Perlorentzou, S. P., Chalkiopoulou, I., Athanasiou, A., Legakis, N. J. (2005). Chryseobacterium indologenes Non-Catheter-Related Bacteremia in a Patient with a Solid Tumor. J. Clin. Microbiol. 43: 2021-2023 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kirby, J. T.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kirby, J. T.
Right arrow Articles by Jones, R. N.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»